Purple BiotechPurple Biotech
  • Home
  • About us
    • Our History
    • Mission
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Overview
    • CM24
    • NT219
    • IM1240
    • Publications
  • Investors
    • Overview
    • News & Events
    • Press Releases
    • SEC Filings
    • Shareholders’ Meetings
    • Email Alerts
    • Corporate Governance
  • Contact us
menu
  • Home
  • About us
  • Pipeline
  • Investors
  • Contact Us
To Top

Category: more about NT-219

Categories

  • News and Events
    • Events
    • News
  • Publications
    • CM-24
    • more about CM-24
    • more about NT-219
    • NT-219

Posts

  • Phase 1 Study of CM24 in Combination with Nivolumab in Patients with Advanced Pancreatic Cancer – Survival, Exploratory Biomarkers and Effect on Neutrophil Extracellular Traps (NETs)
  • Purple Biotech will present a poster titled: ‘Phase 1 Study of CM24 in Combination with Nivolumab in Patients with Advanced Pancreatic Cancer – Survival, Potential Biomarker and Effect on Neutrophil Extracellular Traps (NETs)’ at the AACR Special Conference: Pancreatic Cancer, September 27-30, 2023. Presentation date and time: September 28 at 4:40 pm, 2023
  • Drug Discovery World article on NT219 poster publication on AACR23: “New drug could help overcome tumour resistance to treatment”
  • NT219 induces tumor PD-L1 expression and potentiates anti-PD-1efficacy
  • Purple Biotech to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023.
  • Purple Biotech Presents NT219 Pre-Clinical Data at the AACR 2023 Annual Meeting.
  • Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.
  • Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.
  • Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.
  • Purple Biotech will attend BIO CEO & Investors conference in NYC and will participate in the panel of “Market Outlook – Convincing Hesitant Investors for IPOs Versus Other Capital Alternatives”.

View more: NT-219 References

By yarone
in
more about NT-219
Jan 01, 2021
Download PDF file
Read more
Corporate Headquarters

4 Oppenheimer St.
Science Park, Rehovot
Israel 7670104
Tel : + 972-3-9333121

ir@purple-biotech.com

 

Follow Us
linkedin
Purple biotech
  • Investors
  • Pipeline
  • About us
  • Contact Us

2021 All Rights Reserved. Created BY ATEAS.BIZ

  • Home
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset
We utilize cookies to improve our site and your experience when using it. To find more details, and to know how we obtain, store, and work with your personal data, check our Privacy Policy page.OkNoPrivacy policy
You can revoke your consent any time using the Revoke consent button.Change consent